{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:05:52Z","timestamp":1694149552757},"reference-count":9,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"1","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Antecedentes: La causa m\u00e1s frecuente de hipertiroidismo es la enfermedad de Graves. El propiltiouracilo es\u00a0uno de los medicamentos m\u00e1s prescritos para esta enfermedad. Uno de los efectos adversos dermatol\u00f3gicos\u00a0del propiltiouracilo es la vasculitis leucocitocl\u00e1stica.\nReporte de caso: Paciente femenina de 18 a\u00f1os, al\u00e9rgica al metamizol, con vasculitis asociada a ANCAs, con\u00a0caracter\u00edsticas de vasculitis leucocitocl\u00e1stica provocada por el consumo de propiltiouracilo. No se observ\u00f3\u00a0afectaci\u00f3n sist\u00e9mica. Dos meses despu\u00e9s de suspender el propiltiouracilo desaparecieron casi por completo las lesiones en la piel.\nConclusiones: La vasculitis leucocitocl\u00e1stica debe considerarse en el espectro de complicaciones provocadas\u00a0por el consumo de propiltiouracilo. Las lesiones pueden manifestarse con el paso del tiempo, desde unas semanas\u00a0hasta a\u00f1os despu\u00e9s de consumir el f\u00e1rmaco. Cuando no existe afectaci\u00f3n sist\u00e9mica, la suspensi\u00f3n del\u00a0propiltiouracilo es suficiente para detener la enfermedad.\nPalabras clave: Hipertiroidismo; enfermedad de Graves; propiltiouracilo; vasculitis asociada con anticuerpos\u00a0anti-citoplasma del neutr\u00f3filo; vasculitis leucocitocl\u00e1stica.<\/jats:p>","DOI":"10.29262\/ram.v70i1.1210","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T07:09:15Z","timestamp":1685776155000},"page":"51-54","source":"Crossref","is-referenced-by-count":1,"title":["Vasculitis leucocitocl\u00e1stica como efecto adverso del propiltiouracilo. Reporte de un caso"],"prefix":"10.29262","volume":"70","author":[{"given":"Jos\u00e9 Santiago","family":"Cort\u00e9s-Guzm\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen T.","family":"Veloza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan D.","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Pinz\u00f3n-Tovar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"45570","doi-asserted-by":"crossref","unstructured":"Davies TF, Andersen S, Latif R, et al. Graves\u2019 disease. Nat Rev Dis Prim. 2020;6(1):52. doi:10.1038\/s41572-020-0184-y","DOI":"10.1038\/s41572-020-0184-y"},{"key":"45571","doi-asserted-by":"crossref","unstructured":"McDermott MT. Hyperthyroidism. Ann Intern Med. 2020;172(7):ITC49. doi:10.7326\/AITC202004070","DOI":"10.7326\/AITC202004070"},{"key":"45572","doi-asserted-by":"crossref","unstructured":"Miao Y, Xu Y, Teng P, et al. Efficacy of propylthiouracil in the treatment of pregnancy with hyperthyroidism and its effect on pregnancy outcomes: A meta-analysis. Saokaew S, ed. PLoS One. 2022;17(3):e0265085. doi:10.1371\/journal.pone.0265085","DOI":"10.1371\/journal.pone.0265085"},{"key":"45573","unstructured":"Amisha F, Rehman A. Propylthiouracil (PTU). StatPearls Publishing; 2022. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31751018"},{"key":"45574","doi-asserted-by":"crossref","unstructured":"Zambernardi A, Label M. Reacciones cut\u00e1neas adversas a medicamentos: c\u00f3mo identificar el desencadenante. Actas Dermosifiliogr. 2018;109(8):699-707. doi:10.1016\/j.ad.2018.02.017","DOI":"10.1016\/j.ad.2018.02.017"},{"key":"45575","doi-asserted-by":"crossref","unstructured":"Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med. 2021;16(4):831-841. doi:10.1007\/s11739-021-02688-x","DOI":"10.1007\/s11739-021-02688-x"},{"key":"45576","doi-asserted-by":"crossref","unstructured":"Kayser C, Dutra LA, dos Reis-Neto ET, Castro CH de M, Fritzler MJ, Andrade LEC. The Role of Autoantibody Testing in Modern Personalized Medicine. Clin Rev Allergy Immunol. Published online March 4, 2022. doi:10.1007\/s12016-021-08918-6","DOI":"10.1007\/s12016-021-08918-6"},{"key":"45577","doi-asserted-by":"crossref","unstructured":"Almeida MS, Ramalho C, Gomes F, Ginga M do R, Vilchez J. Propylthiouracil-Induced Skin Vasculitis. Cureus. Published online July 20, 2022. doi:10.7759\/cureus.27073","DOI":"10.7759\/cureus.27073"},{"key":"45578","doi-asserted-by":"crossref","unstructured":"Lam B, Yuile A, Fernando SL. Propylthiouracil\u2010induced vasculitis in carbimazole\u2010refractory Graves disease. Med J Aust. 2019;210(11):491. doi:10.5694\/mja2.50198","DOI":"10.5694\/mja2.50198"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T07:09:21Z","timestamp":1685776161000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v70i1.1210","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"value":"2448-9190","type":"electronic"},{"value":"0002-5151","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,24]]}}}